Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ticagrelor China Pharmacokinetic/Pharmacodynamic Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT02064985
First received: February 12, 2014
Last updated: April 5, 2016
Last verified: March 2016
  Purpose
open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese patients with stable coronary heart disease

Condition Intervention Phase
Stable Coronary Heart Disease (CHD)
Drug: Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • IPA on Day 1 [ Time Frame: Baseline and at 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours,48 hours after dose intake on Day 1 ] [ Designated as safety issue: No ]

    The Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).

    Primary variable: IPA (final extent) induced by 20µM ADP at each assessment point after single and multiple doses of ticagrelor measured by Light-Transmittance Aggregometry (LTA).


  • IPA on Day 7 [ Time Frame: Baseline and at 0 hour, 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours after dose intake on Day 7 ] [ Designated as safety issue: No ]

    The inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).

    Primary variable: IPA (final extent) induced by 20µM ADP at each assessment point after single and multiple doses of ticagrelor measured by Light-Transmittance Aggregometry (LTA).



Secondary Outcome Measures:
  • Percent Change From Baseline in PRU on Day 1 [ Time Frame: Baseline and at 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours,48 hours after dose intake on Day 1 ] [ Designated as safety issue: No ]
    Percent Change from baseline in Platelet P2Y12 Reaction Units (PRU)(measured by VerifyNow) profiles of multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease on chronic low dose ASA.

  • Pharmacokinetics Parameters of Ticagrelor on Day 7(1) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of Ticagrelor on Day 7---Cmax

  • Safety---Vital Signs Over Time---Blood Pressure [ Time Frame: Baseline, Day 1 to Day 7 and 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Vital signs (seated blood pressure [BP])


  • Percent Change From Baseline in PRU on Day 7 [ Time Frame: Baseline and at 0 hour, 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours after dose intake on Day 7 ] [ Designated as safety issue: No ]
    Percent Change from baseline in Platelet P2Y12 Reaction Units (PRU)(measured by VerifyNow) profiles of multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease on chronic low dose ASA.

  • TIPA(Max)---Day 1 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    The time to peak IPA (TIPAmax) was estimated for ADP-induced final extent IPA.

  • TIPA(Max)---Day 7 [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
    The time to peak IPA (TIPAmax) was estimated for ADP-induced final extent IPA.

  • AUEC(Final Extent) on Day 1 [ Time Frame: IPA was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1 ] [ Designated as safety issue: No ]
    The area-under-the-effect curve (AUEC) was estimated for ADP-induced final extent IPA.

  • AUEC(Final Extent) on Day 7 [ Time Frame: IPA was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    The area-under-the-effect curve (AUEC) was estimated for ADP-induced final extent IPA.

  • Pharmacokinetics Parameters of Ticagrelor on Day 1(3) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1 ] [ Designated as safety issue: No ]
    The pharmacokinetics parameter of ticagrelor on Day 1---tmax and t1/2

  • Pharmacokinetics Parameters of Ticagrelor on Day 1(2) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1 ] [ Designated as safety issue: No ]
    The pharmacokinetics parameters of Ticagrelor on Day 1---AUC(0-inf), AUC(0-12h) and AUC(0-t).

  • Pharmacokinetics Parameters of Ticagrelor on Day 7(2) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    The pharmacokinetics parameters of ticagrelor on Day 7---tmax

  • Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(1) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1---Cmax

  • Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(3) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1: tmax and t1/2

  • Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(1) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---Cmax

  • Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(4) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 7---tmax

  • Pharmacokinetics Parameters of Metabolite : Parent on Day 1--Cmax [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    To determine Cmax ratio for the metabolite to that of the parent compound on Day 1

  • Pharmacokinetics Parameters of Metabolite : Parent on Day 7---Cmax [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
    To determine Cmax ratio of metabolite to that of the parent compound on Day 7

  • Safety---Physical Examination, Summary of Abnormalities [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Physical examination


  • Safety---Hematology Laboratory Variables Over Time---hematocrit [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Haematology---hematocrit


  • Safety---All Allowed Concomitant Medications During Study Treatment [ Time Frame: All allowed concomitant medications during study treatment(up to 2-5 days after last dose), includes medications that began prior to randomization but were ongoing after randomization. ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Concomitant medications


  • Safety---Causally Related Adverse Events by System Organ Class and Preferred Term [ Time Frame: Includes adverse events with an onset date on or after the date of first dose and up to and including the last study visit (up to 2-5 days after last dose). ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Assessment of adverse events


  • Pharmacokinetics Parameters of Ticagrelor on Day 1(1) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1 ] [ Designated as safety issue: No ]
    The pharmacokinetics parameters of Ticagrelor on Day 1---Cmax

  • Pharmacokinetics Parameters of Ticagrelor on Day 7(3) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of Ticagrelor on Day 7---AUC(0-12h)

  • Pharmacokinetics Parameters of Ticagrelor on Day 7(4) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of Ticagrelor on Day 7---Accumulation ratio(ratio of Day 7 AUC(0-12h) to Day 1 AUC(0-12h))

  • Safety---Vital Signs Over Time---Height [ Time Frame: Baseline ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Vital signs (Height)


  • Safety---Vital Signs Over Time---Weight [ Time Frame: Baseline ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Vital signs (Weight)


  • Safety---Vital Signs Over Time---Pulse Rate [ Time Frame: Baseline, Day 1 to Day 7 and 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Vital signs (Pulse Rate)


  • Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(2) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1---AUC(0-12h), AUC(0-t) and AUC(0-inf)

  • Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(2) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---AUC(0-12h)

  • Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(3) [ Time Frame: Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7 ] [ Designated as safety issue: No ]
    Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---Accumulation ratio(ratio of Day 7 AUC(0-12h) to Day 1 AUC(0-12h))

  • Safety---Hematology Laboratory Variables Over Time---Erythrocytes [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Haematology---Erythrocytes


  • Safety---Hematology Laboratory Variables Over Time---Hemoglobin [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Haematology---Hemoglobin


  • Safety---Hematology Laboratory Variables Over Time---Leukocytes [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Haematology---Leukocytes


  • Safety---Hematology Laboratory Variables Over Time---Platelets [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Haematology---Platelets


  • Safety---Clinical Chemistry Variables Over Time---Glucose [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Glucose


  • Safety---Clinical Chemistry Variables Over Time---Alanine Aminotransferase [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Alanine Aminotransferase


  • Safety---Clinical Chemistry Variables Over Time---Aspartate Aminotransferase [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Aspartate Aminotransferase


  • Safety---Clinical Chemistry Variables Over Time---Alkaline Phosphatase [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Alkaline Phosphatase


  • Safety---Clinical Chemistry Variables Over Time---Creatinine [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Creatinine


  • Safety---Clinical Chemistry Variables Over Time---Total Bilirubin [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Total Bilirubin


  • Safety---Clinical Chemistry Variables Over Time---Sodium [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Sodium


  • Safety---Clinical Chemistry Variables Over Time---Potassium [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Potassium


  • Safety---Clinical Chemistry Variables Over Time---Chloride [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Chloride


  • Safety---Clinical Chemistry Variables Over Time---Phosphate [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Phosphate


  • Safety---Clinical Chemistry Variables Over Time---Albumin [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Albumin


  • Safety---Clinical Chemistry Variables Over Time---Protein [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Protein


  • Safety---Clinical Chemistry Variables Over Time---Blood Urea Nitrogen [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Blood Urea Nitrogen


  • Safety---Clinical Chemistry Variables Over Time---Bicarbonate [ Time Frame: 2 to 5 days after last dose ] [ Designated as safety issue: Yes ]

    The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.

    Safety will be assessed by:

    • Clinical Chemistry---Bicarbonate


  • Pharmacokinetics Parameters of Metabolite : Parent on Day 1--AUC(0-inf) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    To determine AUC(0-inf) ratio for the metabolite to that of the parent compound on Day 1

  • Pharmacokinetics Parameters of Metabolite : Parent on Day 7---AUC(0-12h) [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
    To determine AUC(0-12h) ratio of metabolite to that of the parent compound on Day 7.


Enrollment: 61
Study Start Date: February 2014
Study Completion Date: November 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ticagrelor 45mg
A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.
Drug: Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Other Name: "Brilinta"(Ticagrelor)
Experimental: Ticagrelor 60mg
A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.
Drug: Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Other Name: "Brilinta"(Ticagrelor)
Experimental: Ticagrelor 90mg
A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.
Drug: Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Other Name: "Brilinta"(Ticagrelor)

Detailed Description:
Up to 36 patients will be randomized in order to ensure 10 patients per treatment are evaluable.Ticagrelor will be supplied as 45 mg, 60mg, and 90mg tablets. Following an 8 hour fast on single dose on Day 1 and Day 7; on multiple doses from Day 3 to Day 6. Prior to the first dose of study drug there will be a screening period of maximum of 19 days. Patients will report to the clinical pharmacology unit (CPU) on Day -2 and will remain confined there until completion of study procedures on Day 7, the patients will be discharged on Day 8. In addition, patients will return to the CPU for a follow up visit 2 to 5 days after the last dose. Each patients participation, including the screening period, will take approximately 33 days.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of signed and dated written informed consent prior to any study specific procedures.
  2. Female or male Chinese (as defined by Chinese Regulatory) patients aged 18 years or older with suitable veins for cannulations or repeated venipunctures.
  3. Documented stable coronary heart disease (CHD) fulfilling all of the following, and taking 75-100 mg ASA daily treatment:

    Diagnosed stable angina pectoris per the guidance of Chinese Society of Cardiology published in 2007, patients with angina severity classified as I and II of Canadian Cardiovascular Society grading of angina pectoris.

  4. Female patients without pregnant potential

Exclusion Criteria:

  1. Any indication for oral anticoagulant or dual antiplatelet treatment and chronic ASA with doses greater than 100 mg/day.
  2. Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers within 14 days preceding the first dose of study medication and during study treatment.
  3. Increased bleeding risk.
  4. Contraindication or other reason that ASA or ticagrelor should not be administered
  5. Patients that are scheduled for revascularization (eg, PCI, CABG) during the study period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02064985

Locations
China
Research Site
Beijing, China
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Haiyan Li, PhD The 3rd Hospital of Peking University
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02064985     History of Changes
Other Study ID Numbers: D5130C00086 
Study First Received: February 12, 2014
Results First Received: September 2, 2015
Last Updated: April 5, 2016
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Ticagrelor
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on December 06, 2016